Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

ANI Pharmaceuticals, Inc. - Common Stock (NQ:ANIP)

90.32 -0.69 (-0.76%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ANI Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
1 Mooning Stock for Long-Term Investors and 2 That Underwhelm
The stocks featured in this article are seeing some big returns. Over the past month, they’ve outpaced the market due to some combination of positive news, upbeat results, or supportive macro... 
Via StockStory
Topics Emissions
Q2 Earnings Roundup: Viatris (NASDAQ:VTRS) And The Rest Of The Generic Pharmaceuticals Segment
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how generic pharmaceuticals stocks fared in Q2, starting with... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
3 Healthcare Stocks We’re Skeptical Of
Personal health and wellness is one of the many secular tailwinds for healthcare companies. But speed bumps such as inventory destockings have persisted in the wake of COVID-19, and over the past six... 
Via StockStory
Topics Stocks
ANI Pharma Stock Shoots Through The Roof On Friday: CEO’s Confidence On Trump Tariff Impact, Guidance Lift, Upbeat Q2 Among Key Factors
Via Stocktwits
Topics Government
Earnings Preview For ANI Pharmaceuticals
 
Via Benzinga
Azenta, LifeStance Health Group, BioMarin Pharmaceutical, AMN Healthcare Services, and ANI Pharmaceuticals Stocks Trade Up, What You Need To Know
A number of stocks jumped in the afternoon session after markets continued to rally amid growing speculation of an impending interest rate cut by the Federal Reserve. Following a favorable Consumer... 
Via StockStory
Topics Earnings Economy
ANIP Q2 Deep Dive: Rare Disease Expansion Fuels Outperformance, Generics Maintain Solid Trajectory
Specialty pharmaceutical company ANI Pharmaceuticals (NASDAQ:ANIP) reported Q2 CY2025 results beating Wall Street’s revenue expectations, with sales up 53.1% year on year to $211.4 million. The... 
Via StockStory
Why ANI Pharmaceuticals (ANIP) Stock Is Up Today
Shares of specialty pharmaceutical company ANI Pharmaceuticals (NASDAQ:ANIP) jumped 18.4% in the morning session after the company reported second-quarter earnings and revenue that surpassed analyst... 
Via StockStory
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
ANI Pharmaceuticals Inc (NASDAQ:ANIP) Reports Record Q2 2025 Earnings, Beats Estimates and Raises Full-Year Guidance
ANI Pharmaceuticals reports record Q2 2025 earnings, beating estimates with $211.4M revenue and $1.80 EPS. Shares surge 6.5% as company raises full-year guidance. 
Via Chartmill
Topics Earnings
ANI Pharmaceuticals’s (NASDAQ:ANIP) Q2: Strong Sales, Stock Soars
Specialty pharmaceutical company ANI Pharmaceuticals (NASDAQ:ANIP) announced better-than-expected revenue in Q2 CY2025, with sales up 53.1% year on year to $211.4 million. The company’s full-year... 
Via StockStory
Earnings Scheduled For August 8, 2025
 
Via Benzinga
ANI Pharmaceuticals (ANIP) Q2 Earnings: What To Expect
Specialty pharmaceutical company ANI Pharmaceuticals (NASDAQ:ANIP) will be reporting earnings this Friday before the bell. Here’s what to look for. 
Via StockStory
Topics Government World Trade
Delaware Superior Court Jury Issues Unanimous Verdict that CG Oncology Owes No Future Royalties or Other Payments to ANI Pharmaceuticals
From CG Oncology Inc.
Via GlobeNewswire
Q1 Earnings Highs And Lows: Amneal (NASDAQ:AMRX) Vs The Rest Of The Generic Pharmaceuticals Stocks
As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the generic pharmaceuticals industry, including Amneal (NASDAQ:AMRX) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
Q1 Earnings Highs And Lows: Viatris (NASDAQ:VTRS) Vs The Rest Of The Generic Pharmaceuticals Stocks
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how generic pharmaceuticals stocks fared in Q1, starting with... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
3 Value Stocks Skating on Thin Ice
The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued... 
Via StockStory
3 Growth Stocks in Hot Water
Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 will surely remember that the market’s... 
Via StockStory
ANI Pharmaceuticals (NASDAQ:ANIP) Q1 Earnings: Leading The Generic Pharmaceuticals Pack
Wrapping up Q1 earnings, we look at the numbers and key takeaways for the generic pharmaceuticals stocks, including ANI Pharmaceuticals (NASDAQ:ANIP) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
3 of Wall Street’s Favorite Stocks with Questionable Fundamentals
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings,... 
Via StockStory
3 Healthcare Stocks with Mounting Challenges
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But speed bumps such as inventory destockings have persisted in the wake of... 
Via StockStory
Topics Stocks
3 Cash-Producing Stocks in the Doghouse
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak... 
Via StockStory
ANIP Q1 CY2025 Earnings Call: Generics, Rare Disease Drive Growth; Retina Headwinds Noted
Specialty pharmaceutical company ANI Pharmaceuticals (NASDAQ:ANIP) exceeded Wall Street’s revenue expectations in Q1 CY2025, as sales rose 43.4% year on year to $197.1 million. Its non-GAAP EPS of... 
Via StockStory
Topics World Trade
Top 3 Health Care Stocks That Could Lead To Your Biggest Gains This Quarter
 
Via Benzinga
1 Russell 2000 Stock with Solid Fundamentals and 2 to Steer Clear Of
The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential. However, smaller size also means these businesses often lack the... 
Via StockStory
Generic Pharmaceuticals Stocks Q1 In Review: Amphastar Pharmaceuticals (NASDAQ:AMPH) Vs Peers
Wrapping up Q1 earnings, we look at the numbers and key takeaways for the generic pharmaceuticals stocks, including Amphastar Pharmaceuticals (NASDAQ:AMPH) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
3 Value Stocks with Mounting Challenges
Value investing has created more billionaires than any other strategy, like Warren Buffett, who built his fortune by purchasing wonderful businesses at reasonable prices. But these hidden gems are few... 
Via StockStory
3 Small-Cap Stocks Walking a Fine Line
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and their stock prices) often stay small... 
Via StockStory
ANI Pharma Reports Upbeat Q1 Earnings, Revises Full-Year Outlook: Retail’s Pleased
The CEO dismissed the impact of Trump tariffs, noting that the company produces a major portion of its goods in the U.S. 
Via Stocktwits
Topics Government World Trade
Cortrophin Demand Is Soaring For ANI Pharma, CEO Says Well-Positioned To Mitigate Potential Tariff Impact
ANI Pharmaceuticals Q1 revenue rose 43.4% to $197.12 million, EPS beat consensus, and 2025 guidance was raised on strong Cortrophin Gel and generics growth. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.